Garam Kım

This study identifies lipoprotein-mediated endocytosis as a conserved mechanism for cationic cell-penetrating peptides across animal lineages, showing it modulates their antimicrobial function.

This study identifies RTN4R as a regulator of ataxin-2 levels and shows its potential as a therapeutic target for ALS and SCA2.

This study shows that TDP-43 represses a cryptic exon in UNC13A, and genetic variants associated with FTD/ALS increase cryptic exon inclusion when TDP-43 is dysfunctional.

The paper identifies Etidronate, an FDA-approved drug, as a method to lower ataxin-2 levels in neurons using a CRISPR screen and validates its efficacy in mice.

The paper investigates how HNRNPA1 influences U2AF2 RNA binding in vivo, showing it shifts U2AF2 to decoy splice site sequences and affects exon skipping.